Technical analysis of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s ratios


Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) are currently poised at 3.64% from the open today and are trading at $2.85. More than 287,375 shares have exchanged hands compared to an average trading volume of 191.43K. At the current pps, the market cap stands at $131.87M. The stock prices of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) are currently trading at -30.13% below its 52 week high and 18.75% above its 52 week low.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has been in the news for all the right reasons. Recently, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced that Grunenthal, the company’s licensee for ZALVISO® in Europe and Australia, has published two analyses of patient-controlled analgesia (PCA) systems in the peer-reviewed journal, Current Medical Research and Opinion. These manuscripts were based on a systematic literature review of efficacy, safety and tolerability results from studies that were published between 2004 and 2015 of three routes of PCA administration: intravenous (IV) PCA with morphine, transdermal PCA with fentanyl and sublingual sufentanil delivered via ZALVISO. Patients enrolled in these studies had moderate-to-severe acute post-operative pain following surgical procedures such as knee or hip replacement, open abdominal, cardiac, brain, lower limb orthopedic and chest surgery.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is all set to announce its earnings on May 08/a. As per Zack’s analyst ratings, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) currently has an average brokerage rating of 1.8. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:ACRX) is $8.25 with a high of $15 and a low of $4.

Let’s take a look at the technical analysis.

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.

The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The long term and short term EMA’s of 2.72 and 2.82 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term.

The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 57.09 suggesting a bullish price action.

As such, while we believe AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.